Currently, out of the existing stock ratings of Michael Higgins - 42 which are a Buy (82.35%), 8 which are a Hold (15.69%), 1 which are a Sell (1.96%)

Michael Higgins

Work Performance Price Targets & Ratings Chart

Analyst Michael Higgins works at LADENBURG and is covering the Healthcare sector with 100 price targets and ratings displayed on 18 stocks. Previously, Michael Higgins worked at ROTH.

Michael Higgins's average stock forecast success ratio is 38.33% with an average time for price targets to be met of 164.87 days.

Most recent stock forecast was given on MRNS, at 11-Aug-2023.

Wall Street Analyst Michael Higgins

Analyst best performing recommendations are on ZYNE (ZYNERBA PHARMACEUTICALS).
The best stock recommendation documented was for ZYNE (ZYNERBA PHARMACEUTICALS) at 8/8/2017. The price target of $7 was fulfilled within 1 day with a profit of $0.73 (11.64%) receiving and performance score of 116.43.

Average potential price target upside

of $60.87 (285.39%) on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
of $58.4 (44.31%) on NVAX (NOVAVAX).
of $7.09 (90.82%) on RYTM (RHYTHM PHARMACEUTICALS).

ACHV NVAX Novavax PHGE RYTM Rhythm Pharmaceuticals ZYNE Zynerba Pharmaceuticals ACRX AcelRx Pharmaceuticals EIGR Eiger BioPharmaceuticals NTEC SCYX ARCT Arcturus Therapeutics Holdings PTN Palatin Technologies ARTL SAGE Sage Therapeutics VRDN ZGNX Zogenix ATXS MRNS SVRA

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Thomas Flaten (LAKE STREET)